A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a single-centre, phase 1a (dose escalation) and 1b (dose expansion) study to evaluate
the safety and tolerability of oral Selinexor in combination with nivolumab and ipilimumab in
patients with advanced solid malignancies.